Literature DB >> 20804449

Antagonism of eosinophil accumulation in asthma.

Garry M Walsh1.   

Abstract

There is considerable evidence that implicates eosinophils as important effector cells and immunomodulators in the inflammation characteristic of asthma. Numerous in vitro and animal studies have demonstrated essential roles for cell adhesion molecules in eosinophil adhesion and transendothelial migration including the selectins, ICAM-1, VCAM-1 together with many of the 1 and β2 integrins. A large body of evidence has also implicated several cytokines and chemokines in the selective recruitment of eosinophils to sites of asthmatic inflammation. Biopharmaceutical approaches have been used to identify inhibitory molecules that target key elements in the processes controlling eosinophil accumulation in asthma. This review will summarise, the problems and successes regarding recent patents and developments in adhesion-based therapeutic strategies aimed at reducing eosinophil-mediated inflammation in the asthmatic lung.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20804449     DOI: 10.2174/187221310793564263

Source DB:  PubMed          Journal:  Recent Pat Inflamm Allergy Drug Discov        ISSN: 1872-213X


  6 in total

Review 1.  Eosinophil apoptosis and clearance in asthma.

Authors:  Garry M Walsh
Journal:  J Cell Death       Date:  2013-04-17

2.  Pantethine Down-Regulates Leukocyte Recruitment and Inflammatory Parameters in a Mouse Model of Allergic Airway Inflammation.

Authors:  Mhamad Abou-Hamdan; Bouchra Gharib; Marc Bajenoff; Valérie Julia; Max de Reggi
Journal:  Med Sci Monit Basic Res       Date:  2017-11-27

3.  Clinical Outcome of Eosinophilia in Patients with COVID-19: A Controlled Study.

Authors:  Arun Prabhakaran Nair; Ashraf Soliman; Muna A Al Masalamani; Vincenzo De Sanctis; Abdulqadir J Nashwan; Sreethish Sasi; Elrazi A Ali; Ola A Hassan; Fatima M Iqbal; Mohamed A Yassin
Journal:  Acta Biomed       Date:  2020-11-10

4.  Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.

Authors:  Garry M Walsh
Journal:  Biologics       Date:  2013-01-09

5.  Antagonism of cytokine-induced eosinophil accumulation in asthma.

Authors:  Garry M Walsh
Journal:  Front Pharmacol       Date:  2012-11-22       Impact factor: 5.810

Review 6.  Eosinophils: changing perspectives in health and disease.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Paul S Foster
Journal:  Nat Rev Immunol       Date:  2012-11-16       Impact factor: 53.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.